CO [China Cord Blood] F-3:

[] [[Conyers Dill & Pearman(Cayman) Limited letterhead] 8 August 2012 Matter No.:877099 Doc Ref: 1700446 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com China Cord Blood Corporation th 48 1 Garden Road, Central Hong Kong S.A.R. Dear Sirs, Re: China Cord Blood Corporation (the “Company”) Registration Statement Commission Securities Act Ordinary Shares Convertible Notes (the “ We have acted as special Cayman] [Consent of Independent Registered Public Accounting Firm The Board of Directors China Cord Blood Corporation: We consent to the use of our reports dated July 31, 2012, with respect to the consolidated balance sheets of China Cord Blood Corporation and subsidiaries as of March 31, 2011 and 2012, and the related consolidated statements of comprehensive income, changes in equity, and] [9 5层 6层 中国北京市西城区金融大街甲 邮 编码 100033 电话 8610 66523388 传 8610 66523399 5-6/F South Tower, Financial Street Center, A9 Financial Street, Xicheng District, Beijing, 100033, P.R.C. Tel: (8610) 66523388 / Fax: (8610) 66523399 August 8, 2012 China Cord Blood Corporation 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Madams and Sirs, Yours faithfully, JunZeJun]

By | 2016-02-29T14:38:59+00:00 August 8th, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [Chinard Bloodrp] F-3: CALCULATION OF REGISTRATION FEE Titleofeachclassofsecuritiestoberegistered Amounttobe Proposed Proposed

[CALCULATION OF REGISTRATION FEE Titleofeachclassofsecuritiestoberegistered Amounttobe Proposed Proposed Amountof Ordinary shares, par value $0.0001 per share(4) 22,903,454 $ 2.838 $ 65,000,003 $ 7,450 (1) Represents the maximumgregate number of thempanys ordinary shares, par value $0.0001 per share receivable uponnversion of $65,000,000 currently outstandinggregate principal amount of thempanys 7% Seniornvertible Notes due 2017.] [[Conyers Dill & Pearman(Cayman) Limited letterhead] 8 August 2012 Matter No.:877099 Doc Ref: 1700446 Tel No.: 852 2842 9530 E-mail: Richard.Hall@conyersdill.com Chinard Bloodrporation th 48 1 Garden Road, Central Hong KongR. Dear Sirs, Re: Chinard Bloodrporation (thempany) Registration Statementmmission Securities Act Ordinary Sharesnvertible Notes] [Consent of Independent Registered Public Accounting Firm The Board of Directors Chinard Bloodrporation: Wensent to the use of our reportsted July 31, 2012, with respect to thensolidated balance sheets of Chinard Bloodrporation and subsidiaries of March 31, 2011 and 2012, and the relatednsolidated statements ofmprehensiveome, changes in equity, andsh flows for each of the years] [9 5 6 100033 8610 66523388 8610 66523399 5-6/F South Tower, Financial Street Center, A9 Financial Street, Xicheng District, Beijing, 100033, P.R.C. Tel: (8610) 66523388 / Fax: (8610) 66523399 August 8, 2012 Chinard Bloodrporation 48th Floor, Bank of China Tower 1 Garden Road Central Hong KongR. Madams and Sirs,]

By | 2016-02-04T16:48:46+00:00 August 8th, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [China Cord Blood] 20-F: (Original Filing)

[Table of Contents PART I 4 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 4 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 4] [List of Subsidiaries Name Jurisdiction China Cord Blood Services Corporation Cayman Islands China Stem Cells Holdings Limited Cayman Islands Beijing Jiachenhong Biological Technologies Co., Ltd. People’s Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. People’s Republic of China Zhejiang Lukou Biotechnology Co., Ltd. People’s Republic of China China Stem Cells (East) Company Limited British Virgin Islands China Stem] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification I, Albert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of China Cord Blood Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [Certification CHINA CORD BLOOD CORPORATION July 31, 2012 Ting Zheng Chief Executive Officer July 31, 2012 Albert Chen Chief Financial Officer (Principal Financial and Accounting Officer)] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors China Cord Blood Corporation: Hong Kong, China July 31, 2012]

By | 2016-02-29T14:40:38+00:00 July 31st, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [Chinard Bloodrp] 20-F: (Original Filing)

[Table ofntents PART I 4 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT ANDVISERS 4 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 4 ITEM 3. KEY INFORMATION 4 A. Selected Financialta 4 B.pitalization and Indebtedness 8 C. Reasons for the Offer and Use of Proceeds 8 D. Risk Factors] [List of Subsidiaries Name Jurisdiction Chinard Blood Servicesrporationyman Islands China Stem Cellss Limitedyman Islands Beijing Jiachenhong Biological Technologies Peoples Republic of China Guangzhou Municipality Tianhe Nuoya Bio-engineering Peoples Republic of China Zhejiang Lukou Biotechnology Peoples Republic of China China Stem Cells (East)mpany Limited] [Certification I, Ting Zheng, certify that: 1. I have reviewed this annual report on Form 20-F of Chinard Bloodrporation; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [Certification I,bert Chen, certify that: 1. I have reviewed this annual report on Form 20-F of Chinard Bloodrporation; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [Certification CHINARD BLOODRPORATION July 31, 2012 Ting Zheng Chief Executive Officer July 31, 2012bert Chen Chief Financial Officer (Principal Financial and Accounting Officer) v317907_ex13-1.htm 5 EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors Chinard Bloodrporation: Hong Kong, China July 31, 2012 v317907_ex15-1.htm 6 EX-15.1]

By | 2016-02-04T16:51:02+00:00 July 31st, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 4Q12 New Subscribers reached 14,336 4Q12 Net Income Attributable to Shareholders Up 11.3% to RMB29.2 Million Full Year of Fiscal 2012 Operating Cash Flow Increased to RMB353.9 Million Conference Call to be Held June 12, 2012 at 8:00 am ET HONG KONG, China,]

By | 2016-02-29T14:43:13+00:00 June 11th, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] 6-K: China Cord Blood Corporation Reports Financial Results for

[China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 4Q12 New Subscribers reached 14,336 4Q12 Net Income Attributable to Shareholders Up 11.3% to RMB29.2 Million Full Year of Fiscal 2012 Operating Cash Flow Increased to RMB353.9 Million Conference Call to be Held June 12, 2012 at 8:00 am ET HONG KONG, China,]

By | 2016-02-29T14:43:57+00:00 June 11th, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [Chinard Bloodrp] 6-K: (Original Filing)

[Chinard Bloodrporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 4Q12 New Subscribers reached 14,336 4Q12 Netome Attributable to Shareholders Up 11.3% to RMB29.2 Million Full Year of Fiscal 2012 Operatingsh Flowreased to RMB353.9 Millionnferencell to be Held June 12, 2012 at 8:00 am ET]

By | 2016-02-04T17:17:15+00:00 June 11th, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: (Original Filing)

[April 26, 2012 To: KKR China Healthcare Investment Limited c/o KKR Asia Limited Dear Sirs, Re: Lock-Up Agreement dated April 12, 2012 Lock-Up Agreement We refer to the Lock-Up Agreement dated April 12, 2012 (the “ mutatis mutandis The provisions of Sections 5, 6 and 7 of the Lock-Up Agreement are hereby incorporated by reference into this letter and will]

By | 2016-02-29T14:45:00+00:00 May 2nd, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments

CO [China Cord Blood] SC 13D/A: April 26, 2012 To: KKR China Healthcare Investment

[April 26, 2012 To: KKR China Healthcare Investment Limited c/o KKR Asia Limited Dear Sirs, Re: Lock-Up Agreement dated April 12, 2012 Lock-Up Agreement We refer to the Lock-Up Agreement dated April 12, 2012 (the “ mutatis mutandis The provisions of Sections 5, 6 and 7 of the Lock-Up Agreement are hereby incorporated by reference into this letter and will]

By | 2016-02-29T14:45:42+00:00 May 2nd, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CO [Chinard Bloodrp] SC 13D/A: (Original Filing)

[April 26, 2012 To:R China Healthcare Investment Limited c/oRia Limited Dear Sirs, Re: Lock-Upreementted April 12, 2012 Lock-Upreement We refer to the Lock-Upreementted April 12, 2012 (the mutatis mutandis The provisions of Sections 5, 6 and 7 of the Lock-Upreement are herebyorporated by reference into this letter and will apply]

By | 2016-02-04T17:18:48+00:00 May 2nd, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar